Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, T-Cell

Explore clinical trials studying Lymphoma, T-Cell. Study availability and eligibility vary by location and protocol.

181 public trials 52 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, T-Cell trial results

Active, Not Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions
Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details
Active, Not Recruiting

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

NCT02797470

Conditions
Blood-Borne Infections, Burkitt Lymphoma, Communicable Diseases, +41 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UCSF Medical Center-Parnassus San Francisco, California, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Active, Not Recruiting

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

NCT05627245

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +24 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Yale University New Haven, Connecticut, United States
  • University of Kansas Clinical Research Center Fairway, Kansas, United States
  • University of Kansas Cancer Center Kansas City, Kansas, United States
View Trial Details
Active, Not Recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 36 locations
View Trial Details
Active, Not Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

NCT06035497

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +26 more
Locations
  • Local Institution - 0031 Anjo-shi, Aichi-ken, Japan
  • Local Institution - 0011 Nagoya, Aichi-ken, Japan
  • Local Institution - 0024 Toyohashi, Aichi-ken, Japan
  • Local Institution - 0017 Kamogawa, Chiba, Japan
View all 40 locations
View Trial Details
Active, Not Recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

NCT03113500

Conditions
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, +26 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details

Related conditions